
Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

Fungal skin replaces plastics in electronics
In a proof-of-concept study, Doris Danninger and colleagues demonstrate that fungal mycelium skins can be grown and processed to serve as substrates...

Ultra-processed foods increase risk for cancer
According to a long-term data from the UK biobank, high consumption of ultra-processed foods are linked to bad health outcomes such as diabetes,-...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

Abionyx Pharma announces success in fighting sepsis-triggered AKI
After AM-Pharma’s human recombinant alkaline phosphatase, ilofotase alfa, missed the endpoint of improving overall survival in patients with...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...